Skip to Content
Print Share

Generic Auryxia Availability

Auryxia is a brand name of ferric citrate, approved by the FDA in the following formulation(s):

AURYXIA (ferric citrate - tablet;oral)

  • Manufacturer: KERYX BIOPHARMS
    Approval date: September 5, 2014
    Strength(s): EQ 210MG IRON [RLD]

Has a generic version of Auryxia been approved?

No. There is currently no therapeutically equivalent version of Auryxia available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Auryxia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods for treating renal failure
    Patent 5,753,706
    Issued: May 19, 1998
    Inventor(s): Hsu; Chen Hsing
    Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
    Patent expiration dates:
    • February 3, 2017
      ✓ 
      Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
      ✓ 
      Drug product
  • Ferric organic compounds, uses thereof and methods of making same
    Patent 7,767,851
    Issued: August 3, 2010
    Inventor(s): Kwok; David W. K. & Stoynov; Nikolay Mintchev
    Assignee(s): Panion & BF Biotech, Inc.
    The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
    Patent 8,093,423
    Issued: January 10, 2012
    Inventor(s): Chan; Keith & Town; Winston
    Assignee(s): GloboAsia, LLC
    The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
    Patent expiration dates:
    • April 21, 2026
      ✓ 
      Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
  • Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
    Patent 8,299,298
    Issued: October 30, 2012
    Inventor(s): Chan; Keith & Town; Winston
    Assignee(s): Globoasia, LLC
    The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Drug product
  • Ferric organic compounds, uses thereof and methods of making same
    Patent 8,338,642
    Issued: December 25, 2012
    Inventor(s): Kwok; David W. K. & Stoynov; Nikolay Mintchev
    Assignee(s): Panion & BF Biotech, Inc.
    The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Ferric organic compounds, uses thereof and methods of making same
    Patent 8,609,896
    Issued: December 17, 2013
    Assignee(s): Panion & BF Biotech Inc.
    The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Drug product
  • Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
    Patent 8,754,257
    Issued: June 17, 2014
    Assignee(s): Panion & BF Biotech Inc.
    The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Drug product
  • Ferric organic compounds, uses thereof and methods of making same
    Patent 8,754,258
    Issued: June 17, 2014
    Assignee(s): Panion & BF Biotech Inc.
    The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Drug product
  • Ferric organic compounds, uses thereof and methods of making same
    Patent 8,846,976
    Issued: September 30, 2014
    Assignee(s): Panion & BF Biotech Inc.
    The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
  • Ferric organic compounds, uses thereof and methods of making same
    Patent 8,901,349
    Issued: December 2, 2014
    Assignee(s): Panion & BF Biotech Inc.
    The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
  • Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
    Patent 9,050,316
    Issued: June 9, 2015
    Assignee(s): Panion & BF Biotech Inc.
    The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
  • Ferric organic compounds, uses thereof and methods of making same
    Patent 9,328,133
    Issued: May 3, 2016
    Assignee(s): Panion & BF Biotech Inc.
    The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
    Patent expiration dates:
    • February 18, 2024
      ✓ 
      Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Ferric citrate dosage forms
    Patent 9,387,191
    Issued: July 12, 2016
    Assignee(s): Keryx Biopharmaceuticals, Inc.
    Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).
    Patent expiration dates:
    • July 21, 2030
      ✓ 
      Drug product
Add to My Med List

More about Auryxia (ferric citrate)

Consumer resources

Professional resources

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide